- Bachem reports progress on its capacity expansion, with Building K in Bubendorf cleared by regulators and GMP production expected to begin in 2025.
- The company acquired an adjacent property in Vista, California, as part of a $250 million plan (2026–2030) to expand US manufacturing and modernise existing facilities.
Bachem, a peptide and oligonucleotide contract manufacturing partner, has made progress on its global capacity expansion plans. In Bubendorf, Switzerland, Building K passed inspection by local authorities (RHI), with no delays expected. The first GMP batches are scheduled for production in 2025, while commercial production is set to ramp up in 2026. Construction continues in the remaining areas of the building.
In the United States, Bachem acquired a property adjacent to its existing Vista, California, facility to increase future upstream and downstream manufacturing capacity. The company plans to convert the property into a production facility as part of a broader investment of around USD 250 million between 2026 and 2030, which also includes modernising its Torrance site.
The expansion is designed to strengthen Bachem’s presence in the US, the world’s largest healthcare market, and to support its commercial alliances. The Vista site will complement Bachem’s peptide and oligonucleotide contract manufacturing operations and enhance the company’s ability to meet growing global demand.
“I’m very pleased with the progress we are making at Bachem with our capacity expansions. We are right on schedule with Building K, which is not only the largest project for Bachem, but also one of the most modern peptide production facilities in the world.”
Thomas Meier, CEO of Bachem
